Skip to main content
Equibles
CSDX logo

CSDX · Cs Diagnostics Corp.

Track CSDX — free

Use CSDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 At close · Oct 20
Rebalance outlook locked
Going-concern doubt — cleared Apr 15, 2026

The latest filing states the doubt was alleviated.

“These conditions initially raised substantial doubt about the Company’s ability to continue as a going concern within one year from the date the financial statements are issued. ... Accordingly, management has determined that substantial doubt about the Company’s ability to continue as a going concern has been alleviated.”
View the 10-K filed Apr 15, 2026
Market Cap
$54,936
Shares
137.34M
Volume · Oct 20 28.62K Avg daily vol (15 sessions) 18.07K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.01 Open$0.01 Day$0.01–0.01 52W close$0.00–0.40 Avg vol 30d103K Short int1K · 0.0% float · 1.0d Short vol89% DataJan 2020–Oct 2026 Filing10-K · Apr 15

Up next

Latest filing: 10-K
filed Apr 15, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$27,957
Trailing 12 months
Revenue growth YoY
+189.4%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
2.0
Trailing earnings · reciprocal yield 50.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.9%
Year over year · more shares
Price change (1Y)
-99.9%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $7,964 '24 Q3 LATEST ▲189.4% $23,050 −$182 '25 Q3

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −96%
below
Price vs 50-day avg −85%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −85%
trailing
6-month return −97%
trailing
YTD return −98%
this year
Relative strength −105%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 12
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 1918%
annualized · 1-yr
Max drawdown −100%
past year
ATR 261.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−96% Bearish
Price vs 50-day avg
−85% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 2% Range high $0
vs 200-day avg -96% vs 50-day avg -85%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CSDX
Cs Diagnostics Corp.
this stock
$54,936 -97.6% — — 0.0%
ABT
Abbott Laboratories
 $171.24B -18.2% +5.7% 31.8 0.8%
MDT
Medtronic plc
 $121.04B -1.5% +8.4% 23.3 3.1%
SYK
Stryker Corp
 $116.76B -13.4% +11.2% 31.5 1.5%
BSX
Boston Scientific Corp
 $66.02B -52.2% +12.5% 18.4 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
1.4K
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
89%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
15.1K
Value
$1.2K
As of
May 18, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 23, 2026
This year
2
View

Performance

5D 20D 120D MTD YTD
CSDX +1360.0% -85.4% -96.9% -14.1% -97.6%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +1361.2% -84.8% -105.0% -15.0% -110.4%
Key facts CIK 1106861 CUSIP 33852L202 Visit website Investor relations